All
30 July 2020
Seventure’s Health for Life Capital II™ fund qualifies for French government’s financing initiative (“TIBI”) as first and only fund in the microbiome field
Seventure Partners, a European leader in financing innovation, announces today that the technical committee of the French government initiative, which was set up to support...
30 July 2020
Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics,...
27 July 2020
Clim8 raises €2.75m Series A funding
The French company, founded in 2016, is a leader in the connected textiles market with its intelligent and patented thermal technologies. With more than 50% of its sales...
21 July 2020
Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates...
2 July 2020
Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps
OSS, Netherlands-Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration...
2 July 2020
CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS
(BOSTON) – CARB-X announced today that it is awarding up to US$1.82 million to Eligo Bioscience in Paris, France, with additional funding for a total award of up to US$7.05...
25 June 2020
Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...